Alnylam Pharmaceuticals Inc ALNY Phase 2 Diabetes Drug Progress and SP 500 Contender Status Lift Bullish Outlook ESEA Euroseas registers 121 percent Q4 2025 EPS miss sending shares 101 percent lower in todays trading VRM Vroom reports Q3 2025 earnings with no prior analyst consensus shares close unchanged today